| Document |
Document Title |
|
JP2006342186A |
To provide a matrix type transdermal patch for coadministering estradiol and another steroid (wherein, the respective fluxes of estradiol and the other steroid from the matrix are independent of the respective concentrations of the other...
|
|
JP2006527736A |
Method for preparing isotonic estrogen- and gestagen-containing oil emulsion (A) for intravenous administration comprises dissolving the hormones in an oil phase then emulsifying this phase in an aqueous phase, in presence of an emulsifi...
|
|
JP2006526002A |
The invention relates to dialkyltriazene-bearing estrogens and anti-estrogens that are suited for use as chemotherapeutic drugs for treating carcinomas of the sexual organs of humans and animals.
|
|
JP2006526025A |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
|
|
JP3845482B2 |
To isomerize an equilin into a delta (8,9)-dehydroestrone easily convertible to a component of a composite estrogen composition for hormone exchange therapy, etc., by treating an equilin with ethylenediamine Li salt or Li amide. An equil...
|
|
JP2006306896A |
To provide a novel compound having an antiestrogenic action.The novel compound is 17α-alkyl-17β-oxy-estra-1,3,5(10)-triene which is represented by formula I and has an antiestrogenic action. The 17α-alkyl-17β-oxy-estratriene is used ...
|
|
JP3844358B2 |
Novel acridinium esters that are useful, either alone or when incorporated into liposomes, as chemiluminescent agents in binding assays (e.g., immunoassays and gene probe assays) with improved sensitivity are disclosed. In addition, the ...
|
|
JP2006524202A |
This invention relates to 8beta-vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-
trienes of general formula I with ERbeta-antagonistic activity, process for their production, their intermediate products, pharmaceutical preparations...
|
|
JP2006523715A |
The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and an alkylating-type antineoplastic agent.
|
|
JP2006522833A |
The present invention includes methods for treating endometrial hyperplasia and vasomotor symptoms through the administration of estrogenic compounds and progestational agents. The methods presented may include starting estrogen therapy ...
|
|
JP3828926B2 |
PCT No. PCT/EP94/02513 Sec. 371 Date Jan. 18, 1996 Sec. 102(e) Date Jan. 18, 1996 PCT Filed Jul. 28, 1994 PCT Pub. No. WO95/04536 PCT Pub. Date Feb. 16, 1995The invention relates to the use of antiglucocorticoid steroids for the manufact...
|
|
JP3828423B2 |
This invention describes the new 8beta-substituted estratrienes of general formula I in which R2, R3, R6, R6', R7, R7', R9, R11, R11', R12, R14, R15, R15', R16, R16', R17, R17' have the meanings that are indicated in the description, and...
|
|
JP2006522078A |
Dehydro-epiandrosterone (DHEA) derivatives (I) are new. Dehydro-epiandrosterone (DHEA) derivatives (A) are new. [Image] n : 1 or 2; R 1, R 2oxo or -O-W-O-; W : 2-8C linear, branched, cyclic, saturated or unsaturated alkyl (preferably CH ...
|
|
JP3825469B2 |
An inhibitor (A) of cortisol synthesis is used: (a) to treat type II diabetes mellitus; and (b) to counteract other risk factors that are part of the metabolic syndrome (also known as the deadly quartet, syndrome X or insulin resistance ...
|
|
JP3824131B2 |
To obtain a photosensitive compound capable of maintaining a transparent property even under an exposure light source having ≤193 nm short wave length, excellent in adhering capability to a base plate and not only excellent in wettabil...
|
|
JP2006520802A |
A steroid comprising a 17-spirolactone or corresponding open lactone structure is obtained by carbonylation of a 17-alkenyl or 17-alkynyl substrate. A 17-alkenyl intermediate may be prepared by semi-hydrogenation of a 17-alkynyl group. M...
|
|
JP3820150B2 |
A device for local intracoronary delivery comprising 17-beta estradiol or a derivative thereof in a dosage of 1 to 5000 mug/Kg of patient's body weight, and a pharmaceutically acceptable parenteral vehicle
|
|
JP2006520349A |
The disclosed invention relates to sterol and/or stanol esters of ethercarboxylic acids corresponding to general formula (I):R(OAlk)nOCH2COOH, in which R is a C1-50 alkyl, alkenyl and/or alkylphenyl group derived from an alcohol, OAlk st...
|
|
JP3817605B2 |
To simply obtain a fluorine-containing dicarbonyl compound in high yield and selectivity, useful as a synthetic intermediate for agrochemicals or the like. This fluorine-containing dicarbonyl compound represented by formula I (R1 is H, a...
|
|
JP2006519248A |
Disclosed is a process for the synthesis of 17²-hydroxy-7±-methyl- 19-nor-17±-pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof: (11).
|
|
JP3814284B2 |
This invention relates to processes for the preparation of 7-carboxy substituted steroid compounds of Formula I,
|
|
JP3814292B2 |
3-Sulphamoyloxy-oestra-1,3,5(10)-triene derivs. of formula (I) are new. R = NR1R2; R1, R2 = H or 1-5C alkyl; or NR1R2 = 4-6C polymethyleneimino or morpholino; R3 = H or 1-5C alkyl; R4 = H, opt. esterified OH, 1-5C haloalkyl or 1-5C alkox...
|
|
JP2006518715A |
The invention relates to the production and use of novel 14beta-alkyl-18-norsteroids, 8alpha,14beta-dialkyl-18-norsteroids, spiro[cyclopentano-perhydronaphthalin]-3,1'-pentanes or hexanes in addition to 14beta-fluoro-15beta,17beta-dihydr...
|
|
JP2006518393A |
Methods are provided for the treatment of pulmonary hypertension and other conditions associated therewith. In particular, the methods include treatment of pulmonary hypertension with estradiol metabolite or estradiol metabolite associat...
|
|
JP3807680B2 |
PCT No. PCT/EP95/04192 Sec. 371 Date Jun. 25, 1996 Sec. 102(e) Date Jun. 25, 1996 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/13474 PCT Pub. Date May 9, 1996The invention is drawn to a process for the conversion of primary and secondary al...
|
|
JP3803540B2 |
To provide a pigmentation controller for skin and surface-growing bodies, particularly skin decoloration agent and/or bleaching agent in the treatment of the colored spots. In order to control the pigmentation on the skin or their surfac...
|
|
JP2006176427A |
To provide an estrone 3-sulfate transporter activity inhibitor or breast cancer cell proliferation inhibitor or breast cancer curative, with no need of being taken in cells, good in drug delivery tendency and extremely slight in side eff...
|
|
JP2006151994A |
To provide a simple method for converting a pregnane-3,20-dione compound into a 3α-hydroxy-3β-substituted-pregnane.An unprotected dione is chemoselectively and stereoselelctively converted into a 3(R)-pregnane-3-spiro-2'-oxiran-20-one ...
|
|
JP2006514694A |
The present invention is related to acute therapeutic uses of dehydroepiandrosterone (DHEA) congeners. These uses include methods for treating or preventing ulcers which comprise administering to a subject either at risk or in need there...
|
|
JP3770904B2 |
PCT No. PCT/EP93/01606 Sec. 371 Date Apr. 18, 1995 Sec. 102(e) Date Apr. 18, 1995 PCT Filed Jun. 22, 1993 PCT Pub. No. WO94/04553 PCT Pub. Date Mar. 3, 1994.A process for the production of 1-methyl-3-keto- DELTA 1,4 steroids of general f...
|
|
JP3764920B2 |
PURPOSE: To obtain a fluorine-containing steroid useful as a medicine, etc., in a high yield without using a gas difficult to handle by reacting a specific steroid with an electrophilic type fluorinating agent having nitrogen-fluorine bo...
|
|
JP2006508962A |
This invention relates to processes for the preparation of novel 7-carboxy substituted steroid compounds of Formula I,
|
|
JP3756513B2 |
Composition for use in androgenotherapy and having a favorable effect on the prostate hyperplasia. The composition is characterized in that it contains dihydrotestosterone in an administered quantity corresponding to a level of dihydrote...
|
|
JP2006507369A |
The present invention provides 5-androsten-3beta-ol steroid intermediates and processes for their preparation.
|
|
JP3749743B2 |
To obtain the subject safe preparation containing an extract extracted from the fruit of Chaenomeles sinessis Koenne, having an antibacterial activity against hemolytic inflammation-causing bacteria (hemolytic streptococcus) and an activ...
|
|
JP3751705B2 |
To provide a means for normalizing an abnormality in a dermal collagen fascicle caused by the formation of a crease, a fibrosis, a keloid, etc. This dermal collagen fascicular normalizing agent comprises a steroid and its derivative and/...
|
|
JP2006506445A |
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3²-hydroxy-17²-aminoandrost-5-ene, 3...
|
|
JPWO2004035817A1 |
Peroxidation produced by reacting a sample with cholesterol ester hydrolase and cholesterol oxidase, or cholesterol ester hydrolase, oxidized coenzyme and cholesterol dehydrogenase in an aqueous medium containing a bile acid derivative. ...
|
|
JP2006505587A |
The present invention relates to a transdermal hydroalcoholic testosterone gel formulation that overcomes the problems associated with other testosterone delivery mechanisms by providing, among other things, a desirable pharmacokinetic h...
|
|
JP2006505624A |
The present invention involves intermediates, including a 7alpha-substituted steroid (II), and processes which are used to prepare eplerenone, a useful pharmaceutical agent.
|
|
JP2006034215A |
To provide a method for stably producing a drug metabolite by a biological sample fraction originating from a microorganism having a drug metabolic ability.The method for producing the drug metabolite by the biological sample fraction or...
|
|
JP2006504666A |
A pharmaceutical or veterinary composition comprises a non-corticosteroids, and/or salts thereof, and an antimuscarinic (anti-cholinergic) agent, and/or pharmaceutically or veterinarilly acceptable salts thereof. The composition is provi...
|
|
JP3731230B2 |
To provide a new compound produced by reducing a specific aromatic dinitro compound and useful e.g. as a production raw material for a polyimide giving a liquid crystal display element having high durability and heat-resistance and stabl...
|
|
JP2005539016A |
The invention relates to novel compounds of general formula (I), to the production thereof and to pharmaceutical preparations containing these compounds. The inventive compounds are preferably used in female fertility testing and hormone...
|
|
JP2005538030A |
The present invention describes novel compounds of the formula (I):(Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer in combination therapy in a patient. The present invention provides novel compounds useful for the treatment ...
|
|
JP3727332B2 |
Methods of treatment for osteoporosis in a human or other animal subject, comprising: administering a bone-active phosphonate to said subject, at a level of at least about 0.1 LED per day of said treatment; and administering an estrogen ...
|
|
JP3725158B2 |
A method of treating asthma in a subject in need of such treatment is disclosed. The method comprises administering to the subject dehydroepiandrosterone, analogs thereof, or pharmaceutically acceptable salts thereof in an amount effecti...
|
|
JP2005536463A |
The invention relates to compounds of general formula I and the pharmaceutically compatible salts thereof, wherein R1 represents hydrogen, C1- to C6-alkyl, COR4, COOR4, COSR4 or CONHR5, wherein R4 represents C1- to C6-alkyl or unsubstitu...
|
|
JP2005536490A |
A therapy method for treating infertility in a female host, comprising the administration of an ovarian follicular stimulating effective amount of exemestane, is provided.
|
|
JP2005535611A |
The present invention provides novel derivatives comprising compounds in the androstane and androstene series, coupled with ascorbic acid, including salts thereof, and represented by one or more of the general formulae: wherein R1, R2, R...
|
